| Literature DB >> 31454202 |
Shi-Min Yuan1, Hong Lin2.
Abstract
The roles that aortitis plays in the development of annuloaortic ectasia (AAE) remain uncertain, while clinical features of AAE in arteritis are largely unknown. This study was designed to highlight the clinical features of AAE, the treatments of choice, and the causative relations between aortitis and AAE. The morphology of the aortic valve leaflets was normal in half of the patients, while the valves were thin and overstretched in the other half. Most patients had an aortic aneurysm. Half of the patients had severe aortic valve insufficiency, and one-quarter of them had dilation of the sinuses of Valsalva. Takayasu arteritis was prone to develop coronary artery lesions, whereas giant cell arteritis were not. Aortic branch lesions in Takayasu arteritis were stenotic or occlusive in 92.9% of the patients, while in giant cell arteritis, they were all dilated lesions. Most patients (94.7%) required surgical treatment with steroid therapy. However, long-term follow-up results showed a higher anastomotic dehiscence rate, particularly in patients with Takayasu arteritis. Further morphometric and pathological research on AAE in arteritis should be undertaken, and more feasible measures should be warranted for preventing postoperative anastomotic dehiscence.Entities:
Keywords: Aortic Aneurysm; Arteritis; Giant Cell Arteritis; Takayasu Arteritis
Mesh:
Year: 2019 PMID: 31454202 PMCID: PMC6713369 DOI: 10.21470/1678-9741-2018-0252
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Patients' demographics.
| Variable | Result |
|---|---|
| Number of patients, n | 57 |
| Etiology, n (%) | |
| Takayasu arteritis | 42 (73.7) |
| Giant cell aortitis | 15 (26.3) |
| Patients' gender, male/female, n (%) | 11 (22.9)/37 (77.1) |
| Patients' age, year, mean±standard deviation | 41.3±16.6 |
| Age of male patients, years | 42.5±17.9 |
| Age of female patients, years | 40.3±22 |
A comparison between the patients' information from the five case series.
| Amano et al.[ | 8 | 1/7 | 39.4±3.6 (range, 26-57; median, 42) | 8/0 | 2 | 8 | 53.4±4.3 | 24.9±0.5 | |
| Gelsomino | 8 | 0/8 | Circulatory or neurological symptoms (n=8) | 8 | Mean, 40 | Mean, 26.8 | |||
| Masaki et al.[ | 4 | 0/4 | 38-51 | 4/0 | 3 | 4 | |||
| Nakano et al.[ | 8 | 2/6 | 34.4 | 8/0 | 5 | ||||
| Nesi et al.[ | 4 | 0/4 | 72±2.9 (range, 65-78; median, 72.5) | 0/4 | Dyspnea, atrial tachycardia (n=1), episode of heart failure (n=1), chest pain & dyspnea (n=1), respiratory distress (n=1) | 4 | |||
| Amano et al.[ | 54.1±5.3 | Root (n=8) | Bentall operation (n=8) | Died (n=1), recovered (n=7) | |||||
| Gelsomino | Mean, 52 | Root+AA (n=8) | Bentall operation or AVR with AA replacement (n=8); steroid use for 1 year (n=2) | Died (n=1), recovered (n=9) out of 8 AAE patients & 2 non-AAE patients altogether | |||||
| Masaki et al.[ | Obstructive lesions of the aortic arch branch (n=2) | Steroid & AVR (n=4) | Died (n=1), recovered (n=3) | Low cerebral perfusion (n=1) | |||||
| Nakano et al.[ | 67.1 | Coronary artery ectasia (n=2) | Stenosis and/or ectasia of the neck vessels (n=5) | AA (n=8) | Preoperative steroid therapy (n=2); Bentall operation (n=6), Bentall operation + CABG (n=1), Bentall operation + total arch replacement (n=1), postoperative steroid therapy (n=3) | Died (n=1), recovered (n=7) | Pulmonary failure (n=1) | ||
| Nesi et al.[ | AA (n=1), AA + arch (n=2), AA + arch + DA (n=1) | Prolonged cortisone use & AA replacement + AVR (n=1), Bentall operation (n=3) | Died (n=1), recovered (n=3) | Multiple organ failure (n=1) | |||||
AA=ascending aorta; AAE=annuloaortic ectasia; AVR=aortic valve replacement; CABG=coronary artery bypass grafting; DA=descending aorta
Nineteen symptoms presented by 12 patients.
| Symptom | n (%) |
|---|---|
| Dyspnea[ | 5 (26.3) |
| Pain[ | 5 (26.3) |
| Heart failure[ | 3 (15.8) |
| Respiratory distress[ | 1 (5.3) |
| Palpitations[ | 1 (5.3) |
| Malaise[ | 1 (5.3) |
| Chest distress[ | 1 (5.3) |
| Cardiac tamponade[ | 1 (5.3) |
| Atrial tachycardia[ | 1 (5.3) |
Aortic aneurysm in 48 patients with annuloaortic ectasia.
| Aortic aneurysm | n (%) |
|---|---|
| AA[ | 16 (33.3) |
| Root[ | 12 (25.0) |
| Root, AA[ | 8 (16.7) |
| AA, arch[ | 3 (6.3) |
| AA-arch-DA[ | 3 (6.3) |
| Arch[ | 1 (2.1) |
| Root-arch[ | 1 (2.1) |
| Root, arch[ | 1 (2.1) |
| Root, AA, arch, DA[ | 1 (2.1) |
| Root, AA, arch[ | 1 (2.1) |
| Entire aorta[ | 1 (2.1) |
AA=ascending aorta; DA=descending aorta
Cardiac surgical procedures performed in 54 patients with annuloaortic ectasia.
| Cardiac operation | n (%) |
|---|---|
| Bentall[ | 25 (46.3) |
| Bentall/aortic valve replacement + AA
replacement[ | 8 (14.8) |
| Bentall + arch replacement[ | 6 (11.1) |
| AVR[ | 4 (7.4) |
| Bentall + CABG[ | 4 (7.4) |
| AVR + AA replacement[ | 2 (3.7) |
| Cabrol operation[ | 2 (3.7) |
| Bentall + arch replacement + arch branch
replacement[ | 1 (1.9) |
| Bentall + arch + proximal DA
replacement[ | 1 (1.9) |
| Unspecified[ | 1 (1.9) |
AA=ascending aorta; AVR=aortic valve replacement; CABG=coronary artery bypass grafting; DA=descending aorta
A comparison of surgical prognoses between patients with Takayasu arteritis and those with giant cell arteritis.
| Primary disease | Recovered | Complicated | Died |
|---|---|---|---|
| Takayasu arteritis | 31 (79.5) | 4 (10.3) | 4 (10.3) |
| Giant cell arteritis | 12 (85.7) | 0 (0) | 2 (14.3) |
| Χ2 | 0.26 | 1.55 | 0.17 |
| 0.609 | 0.213 | 0.683 |
*Fisher's exact test.
| Abbreviations, acronyms & symbols | ||||
|---|---|---|---|---|
| AA | = Ascending aorta | GCA | = Giant cell aortitis | |
| AAE | = Annuloaortic ectasia | IgA | = Immunoglobulin A | |
| AVR | = Aortic valve replacement | IgG | = Immunoglobulin G | |
| C3 | = Component 3 | PRISMA | = Preferred Reporting Items for Systematic Reviews and Meta-analyses | |
| C4 | = Component 4 | TA | = Takayasu arteritis | |
| CABG | = Coronary artery bypass grafting | |||
| DA | = Descending aorta | |||
| Author's roles & responsibilities | |
|---|---|
| SMY | Conception or design of the work; acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |
| HL | Interpretation of data for the work; final approval of the version to be published |